SOURCE-LINKED INTELLIGENCE

Automated, miniaturized and accelerated drug discovery: AMADEUS

CORDIS · observation · Publication date unknown

o synthesize in a fully autonomous manner thousands of small molecules per day in nano- or picolitre volumes, based on hundreds of chemistries, efficiently screened and optimized for properties using artificial intelligence. The AMADEUS process will be achieved by interfacing four different modules: a synthetic part based on acoustic droplet ejection technology, coupled with a UPLC MS QC and purification module, and a flexible mounted screening unit. A machine learning module will retrieve and process all relevant synthesis, QC, and screening ‘real-time’ data and automatically guide the iterative optimization cycle. AMADEUS will be showcased with several medicinal chemistry, catalysis, and organic chemistry projects. With my project, I want to challenge the early drug discovery process, which for over 50 years in pharma companies around the world has (almost uniformly) been pursued and comprises two blocks, 1) a high throughput screen relying on millions of curated and stored compounds and 2) the subsequent hit-to-lead optimization phase often called the ‘design, make, test cycle’.

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

3409401

unit

EUR